Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-07-034017PMID 17038522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders - European Patent Office EP2100619 A1

  2009cited by this paper
• Potent antibody therapeutics by design

  2006cited by this paper
• Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

  2006cited by this paper
• Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas

  2005cited by this paper
• Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry.

  2005cited by this paper
• A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

  2005cited by this paper
• Induction of CD70 on Dendritic Cells through CD40 or TLR Stimulation Contributes to the Development of CD8+ T Cell Responses in the Absence of CD4+ T Cells1

  2005cited by this paper
• Concurrent administration of granulocyte colony-stimulating factoror granulocyte-monocyte colony-stimulating factor enhancesthe biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

  2005cited by this paper
• Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1

  2005cited by this paper
• CD70 Signaling Is Critical for CD28-Independent CD8+ T Cell-Mediated Alloimmune Responses In Vivo1

  2005cited by this paper
• Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post‐transplant EBV‐associated autoimmune hemolytic anemia

  2005cited by this paper
• Increased prevalence of activated CD70+CD4+ T cells in the periphery of patients with systemic lupus erythematosus

  2005cited by this paper
• Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

  2005cited by this paper
• CD70: a new tumor specific biomarker for renal cell carcinoma.

  2005cited by this paper
• Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

  2005cited by this paper
• Lenalidomide and thalidomide: mechanisms of action--similarities and differences.

  2005cited by this paper
• Signaling through CD70 Regulates B Cell Activation and IgG Production

  2004cited by this paper
• Anti-CD70 antibody-drug conjugates and their

  2004cited by this paper
• CD27 Is Acquired by Primed B Cells at the Centroblast Stage and Promotes Germinal Center Formation1

  2004cited by this paper
• High Levels of Soluble Immunoregulatory Receptors in Patients with WaldenströM’s Macroglobulinemia.

  2004cited by this paper
• Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma

  2004cited by this paper
• Signalling via CD70, a member of the TNF family, regulates T cell functions

  2004cited by this paper
• Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

  2004cited by this paper
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

  2004cited by this paper
• Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors.

  2004cited by this paper
• Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions

  2003cited by this paper
• CD27/CD70, CD134/CD134 ligand, and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigen

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

  2003cited by this paper
• Rituximab treatment results in impaired secondary humoral immune responsiveness.

  2002cited by this paper
• Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

  2002influential reference
• Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma.

  2002cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors

  2002cited by this paper
• Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion.

  2001cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• CD70 expression in thymic carcinoma.

  2000cited by this paper
• Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis.

  2000cited by this paper
• Critical Contribution of Ox40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis

  2000cited by this paper
• CD27 is required for generation and long-term maintenance of T cell immunity

  2000cited by this paper
• Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities

  1999cited by this paper
• Aberrant expression and reverse signalling of CD70 on malignant B cells

  1999cited by this paper
• CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

  1998cited by this paper
• Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction.

  1998cited by this paper
• CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling.

  1997cited by this paper
• Elimination, blocking, and activation of macrophages: three of a kind?

  1997cited by this paper
• CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation.

  1997cited by this paper
• Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells.

  1995cited by this paper
• Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

  1994cited by this paper
• The cloning of CD70 and its identification as the ligand for CD27.

  1994cited by this paper
• CD5 expression in thymic carcinoma.

  1994cited by this paper
• Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor.

  1993cited by this paper
• Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysis

  1992cited by this paper
• Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities

  1990cited by this paper
• Leucocyte typing IV : white cell differentiation antigens

  1989cited by this paper

• The Role of CD70 Expression in Lymphoma Pathogenesis, Progression and Treatment.

  2025cites this paper
• Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential

  2025influential citation
• CAR T therapies in multiple myeloma: unleashing the future

  2024cites this paper
• Cellular Therapies for Multiple Myeloma: Engineering Hope

  2024cites this paper
• Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

  2023cites this paper
• Tailoring biomaterials and applications targeting tumor-associated macrophages in cancers

  2022cites this paper
• CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets

  2022cites this paper
• Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer

  2022cites this paper
• Identification and characterization of blocking nanobodies against human CD70

  2022cites this paper
• The CD70-CD27 axis in oncology: the new kids on the block

  2022cites this paper
• Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma

  2021cites this paper
• CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer

  2021cites this paper
• Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism

  2021cites this paper
• Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

  2019cites this paper
• Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

  2018influential citation
• CARs and other T cell therapies for MM: The clinical experience.

  2018cites this paper
• Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target

  2018cites this paper
• Applications of AFM Cellular and Molecular Biophysical Detection in Clinical Lymphoma Rituximab Treatment

  2018cites this paper
• Peptides in immunoengineering

  2018cites this paper
• Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells

  2018cites this paper
• The Clinical Significance of HPRT as a Diagnostic and Therapeutic Biomarker for Hematological and Solid Malignancies

  2018cites this paper
• The expansion of targetable biomarkers for CAR T cell therapy

  2018cites this paper
• Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma

  2017cites this paper
• Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

  2017cites this paper
• Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

  2017cites this paper
• Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation

  2017cites this paper
• Therapeutic targeting of CD70 and CD27

  2016cites this paper
• Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma

  2016cites this paper
• Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies

  2016cites this paper
• Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

  2015cites this paper
• Expression of the immune regulation antigen CD70 in osteosarcoma

  2015cites this paper
• First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

  2015cites this paper
• Innate immune responses of natural killer cells and macrophages against bone sarcomas : towards cellular immunotherapy

  2014cites this paper
• Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

  2014cites this paper
• Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

  2014cites this paper
• Epithelial Membrane Protein-2 (EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma*

  2014cites this paper
• Nanoscale imaging and mechanical analysis of Fc receptor-mediated macrophage phagocytosis against cancer cells.

  2014cites this paper
• Pyrosequencing for Classification of Human FcγRIIIA Allotypes: A Comparison with PCR-Based Techniques

  2014cites this paper
• Myeloid cells as effector cells for monoclonal antibody therapy of cancer.

  2014cites this paper
• Evaluation of complement-dependent cytotoxicity using ATP measurement and C1q/C4b binding.

  2013cites this paper
• Development of orally active inhibitors of protein and cellular fucosylation

  2013cites this paper
• The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B‐cell lymphoma

  2013cites this paper
• Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies

  2013cites this paper
• Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study

  2013cites this paper
• Clinical targeting of the TNF and TNFR superfamilies

  2013cites this paper
• Interleukin-21 Enhances Rituximab Activity in a Cynomolgus Monkey Model of B Cell Depletion and in Mouse B Cell Lymphoma Models

  2013cites this paper
• Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma

  2013cites this paper
• Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy

  2013cites this paper
• Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

  2013cites this paper
• SGN-30 Macrophages contribute to the antitumor activity of the anti-CD30 antibody

  2013cites this paper
• Introduction: Antibody Structure and Function

  2013cites this paper
• Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27

  2013cites this paper
• 1 Introduction : Antibody Structure and Function

  2013cites this paper
• Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation.

  2013cites this paper
• Anti-Tumor Function Invasion while Retaining Fc-Dependent Tumor-Associated Macrophages Promote

  2012cites this paper
• hematologic malignancies and exhibits potent in vitro and in vivo antitumor activity against Fc-engineered anti-CD40 antibody enhances multiple effector functions

  2012cites this paper
• Aggressive peripheral CD70‐positive t‐cell lymphoma associated with severe chronic active EBV infection

  2012cites this paper
• Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics

  2012cites this paper
• Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function

  2012cites this paper
• T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

  2011cites this paper
• Tumor‐derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation

  2011cites this paper
• Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains.

  2011cites this paper
• Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.

  2011influential citation
• Expression of Surface Molecules on Multiple Myeloma Cells and their Potential Role in Pathogenesis, Prognosis, and Treatment

  2011cites this paper
• Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease

  2011cites this paper
• Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

  2011cites this paper
• Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies

  2011cites this paper
• The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge

  2011cites this paper
• Two-Step In Vivo Tumor Targeting by Biotin-Conjugated Antibodies and Superparamagnetic Nanoparticles Assessed by Magnetic Resonance Imaging at 1.5 T

  2010cites this paper
• Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

  2010cites this paper
• 5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

  2010cites this paper
• UvA-DARE ( Digital Academic Repository ) Molecular mechanisms underlying CD 27-CD 70 costimulation

  2010cites this paper
• New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression

  2010cites this paper
• Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.

  2010cites this paper
• Molecular mechanisms underlying CD27-CD70 costimulation

  2010cites this paper
• Optimization of Fc-mediated effector functions of monoclonal antibodies.

  2009cites this paper
• Targeting CD70 for human therapeutic use.

  2009cites this paper
• Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology

  2009cites this paper
• Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia.

  2009cites this paper
• Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia

  2009cites this paper
• Modulating T cell homeostasis via TNF and TNFR superfamily members : characterization and function of effector & regulatory T cells

  2009cites this paper
• Therapeutic targets of the TNF superfamily

  2009cites this paper
• Antibody-drug conjugate targets.

  2009cites this paper
• Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis

  2009cites this paper
• Disease in Murine Collagen-Induced Arthritis Anti-CD70 Antibody Ameliorates Joint Blocking of CD27-CD70 Pathway by

  2009cites this paper
• Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis

  2009influential citation
• Antibodies for therapeutic uses and the evolution of biotechniques.

  2009cites this paper
• The role of TNF superfamily members in T-cell function and diseases

  2009cites this paper
• Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.

  2009cites this paper
• Generation and validation of affinity reagents on a proteome‐wide level

  2009cites this paper
• MR and Iron Magnetic Nanoparticles. Imaging Opportunities in Preclinical and Translational Research

  2008cites this paper
• Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

  2008cites this paper
• Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand.

  2008cites this paper
• Macroglobulinemia CD27-CD70 interactions in the pathogenesis of Waldenstrom's

  2008cites this paper
• CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

  2008cites this paper
• Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

  2008cites this paper
• Anti‐CD20 monoclonal antibody therapy in multiple myeloma

  2008cites this paper
• An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients

  2008cites this paper
• Highly Enhanced Expression of CD70 on Human T-Lymphotropic Virus Type 1-Carrying T-Cell Lines and Adult T-Cell Leukemia Cells

  2008cites this paper
• Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

  2008cites this paper